MedPath

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Phase 2
Active, not recruiting
Conditions
Plaque Psoriasis
Interventions
Drug: ESK-001
Registration Number
NCT05739435
Lead Sponsor
Alumis Inc
Brief Summary

This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.

Detailed Description

This study will consist of patients who have completed their participation in a previous plaque psoriasis study of ESK-001. Each patient will be assigned to receive ESK-001 at one of two open-label dose levels. Patients have the option to remain on study until ESK-001 is commercially available.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
165
Inclusion Criteria
  • Must have completed a prior ESK-001 study
  • Men and Women must use highly effective methods of contraception for the entirety of the study
Read More
Exclusion Criteria
  • Pregnancy
  • Received a prohibited concomitant medication
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ESK-001 Dose Level 2ESK-001ESK-001 administered as an oral tablet
ESK-001 Dose Level 1ESK-001ESK-001 administered as an oral tablet
Primary Outcome Measures
NameTimeMethod
To assess the safety and tolerability of long-term ESK-001 treatmentApproximately 3 years

Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

Secondary Outcome Measures
NameTimeMethod
To assess the long-term efficacy of ESK-001Approximately 3 years

Change from baseline in Psoriasis Area and Severity Index (PASI) over time

To assess the change in quality of life (QoL) with long-term ESK-001 administrationApproximately 3 years

Change from baseline in Dermatology Life Quality Index (DLQI) over time

To assess the pharmacokinetics (PK) of ESK-001 (ctrough)2 years

Plasma concentrations and PK parameters including steady-state trough observed plasma concentration (Ctrough) for ESK-001

Trial Locations

Locations (38)

Investigator Site #1018

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

Investigator Site #1035

πŸ‡ΊπŸ‡Έ

Macon, Georgia, United States

Investigator Site #1017

πŸ‡ΊπŸ‡Έ

Owensboro, Kentucky, United States

Investigator Site # 2004

πŸ‡¨πŸ‡¦

Mississauga, Ontario, Canada

Investigator Site #1025

πŸ‡ΊπŸ‡Έ

Hialeah, Florida, United States

Investigator Site #1022

πŸ‡ΊπŸ‡Έ

Philadelphia, Pennsylvania, United States

Investigator Site #1031

πŸ‡ΊπŸ‡Έ

New Brighton, Minnesota, United States

Investigator Site #1015

πŸ‡ΊπŸ‡Έ

Houston, Texas, United States

Investigator site # 1028

πŸ‡ΊπŸ‡Έ

Miami, Florida, United States

Investigator Site #2003

πŸ‡¨πŸ‡¦

Winnipeg, Manitoba, Canada

Investigator SIte#1036

πŸ‡ΊπŸ‡Έ

Overland Park, Kansas, United States

Investigator Site #1001

πŸ‡ΊπŸ‡Έ

Phoenix, Arizona, United States

Investigator Site # 1023

πŸ‡ΊπŸ‡Έ

Rogers, Arkansas, United States

Investigator Site # 2008

πŸ‡¨πŸ‡¦

Surrey, British Columbia, Canada

Investigator Site # 1012

πŸ‡ΊπŸ‡Έ

Rapid City, South Dakota, United States

Investigator Site # 1029

πŸ‡ΊπŸ‡Έ

Birmingham, Alabama, United States

Investigator Site #1019

πŸ‡ΊπŸ‡Έ

Portland, Oregon, United States

Investigator Site #1021

πŸ‡ΊπŸ‡Έ

Encinitas, California, United States

Investigator site # 1030

πŸ‡ΊπŸ‡Έ

Fort Lauderdale, Florida, United States

Investigator Site #1002

πŸ‡ΊπŸ‡Έ

Sherman Oaks, California, United States

Investigator Site #1043

πŸ‡ΊπŸ‡Έ

Sandy Springs, Georgia, United States

Investigator Site #1005

πŸ‡ΊπŸ‡Έ

Rolling Meadows, Illinois, United States

Investigator Site # 1011

πŸ‡ΊπŸ‡Έ

Columbus, Indiana, United States

Investigator Site #1026

πŸ‡ΊπŸ‡Έ

Rockville, Maryland, United States

Investigator Site #1033

πŸ‡ΊπŸ‡Έ

Norman, Oklahoma, United States

Investigator Site #1010

πŸ‡ΊπŸ‡Έ

Clarkston, Michigan, United States

Investigator Site # 1006

πŸ‡ΊπŸ‡Έ

San Antonio, Texas, United States

Investigator Site # 1041

πŸ‡ΊπŸ‡Έ

South Jordan, Utah, United States

Investigator Site #2006

πŸ‡¨πŸ‡¦

London, Ontario, Canada

Investigator Site # 2007

πŸ‡¨πŸ‡¦

North Bay, Ontario, Canada

Investigator Site #2009

πŸ‡¨πŸ‡¦

Toronto, Ontario, Canada

Investigator Site #2005

πŸ‡¨πŸ‡¦

Oakville, Ontario, Canada

Investigator Site # 2002

πŸ‡¨πŸ‡¦

Waterloo, Ontario, Canada

Investigator Site # 2010

πŸ‡¨πŸ‡¦

Quebec, Canada

Investigator Site #1027

πŸ‡ΊπŸ‡Έ

South Bend, Indiana, United States

Investigator Site #1007

πŸ‡ΊπŸ‡Έ

Santa Monica, California, United States

Investigator Site # 1013

πŸ‡ΊπŸ‡Έ

Tampa, Florida, United States

Investigator Site #2001

πŸ‡¨πŸ‡¦

Edmonton, Alberta, Canada

Β© Copyright 2025. All Rights Reserved by MedPath